Detecting more prostate cancer earlier with PSMA PET Scans May 24, 2023 Prostate cancer doesn't always require aggressive treatment. Most men can delay complex treatment until necessary through Active Surveillance according to a ne... Continue Reading
Healthcare Hero: Kara Cossis, Chesapeake Urology April 12, 2023 At Myriad Genetics, our mission is to advance health and well-being for all, and a big component of that is developing reliable, accessible genetic tests for a... Continue Reading
Medical Experts Discuss Benefits of Genetic Testing in Prostate Cancer Care March 23, 2023 In a recent Myriad Live webinar, our Chief Medical Officer, Thomas Slavin, hosted a lively conversation about prostate cancer with two experts from the field: ... Continue Reading
Expanding access to PARP inhibitors in prostate cancer treatment March 14, 2023 Last month, Myriad attended the 2023 ASCO Genitourinary Cancers Symposium (ASCO GU) to connect with researchers and doctors around emergent and controversial a... Continue Reading
Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why. September 16, 2022 Prolaris: Your NEW ADT decision tool When it comes to treating NCCN intermediate- and high-risk prostate cancer, it can be challenging to know which patien... Continue Reading
Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why. August 26, 2022 Treating prostate cancer can be hard, Prolaris makes it easy Knowing if your prostate cancer patients are safe for active surveillance or if they would bene... Continue Reading
Myriad Genetics is committed to being your partner of choice August 5, 2022 Against the backdrop of recent shifts in the genetic testing industry, we would like to take a minute to reiterate Myriad Genetics’ determination to bring cl... Continue Reading
Genetic insights for more actionable and personalized prostate cancer March 25, 2022 Connect with us The AUA National meeting is centered around the exploration of the latest and groundbreaking advancements in urology, and th... Continue Reading
Prolaris® is advancing prostate cancer care at ASCO GU February 11, 2022 Prolaris now has 2 validated thresholds to make treatment decisions easier Prolaris is a prognostic, tumor-based biomarker test that measures the aggressive... Continue Reading
Prolaris® is Helping Urologists Reimagine Prostate Cancer Care November 2, 2021 This year’s LUGPA theme centers on re-imagining the practice of Urology. What better time than now to discover how incorporating genetic testing into your pr... Continue Reading
New Study Proves that Prolaris can Determine which Patients Can Safely Avoid ADT October 15, 2021 Historically, Urologists in practice have given Radiation Therapy (RT) or Androgen Deprivation Therapy (ADT) after initial prostate cancer treatment to red... Continue Reading
New Data Validating the Prolaris® Test to Guide Treatment for Prostate Cancer February 17, 2021 Myriad Genetics announces new data validating the prognostic power of the Prolaris multi-modal threshold and its ability to help predict which men with agg... Continue Reading
1 in 6 Men with Prostate Cancer May Have a Hereditary, Disease-Causing Mutation September 17, 2020 Knowing the status of your patient’s BRCA 1/2 germline status is critical. Myriad hereditary cancer tests give you definitive and actionable risk stratificat... Continue Reading
New Treatment Options Available September 9, 2020 Every man with prostate cancer deserves to know his germline BRCA 1/2 status and recent changes now make that possible and easier than ever. Medicare has expan... Continue Reading
Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer September 1, 2020 Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis CDx® for men with pr... Continue Reading